T-cell immunotherapy is a promising strategy to treat cancer, but its efficacy, complexity, and costs may pose challenges. In this study, we report the results of an investigation of a new approach to selectively activate a Tcell attack against tumor cells. The immunotherapeutic approach we developed utilizes a bifunctional fusion protein that binds tumor cells through NK (natural killer)-activating receptor NKG2D and that recruits and stimulates T cells through an anti-CD3 single-chain variable fragment (scFv-NKG2D). In vitro, this scFv-NKG2D fusion protein engaged both T cells and tumor cells, stimulating T cells to produce IFN-g, and cytotoxicity against NKG2D ligand-positive tumor cells. In vivo, expression of scFv-NKG2D by NKG2D ligand-positive tumor cells reduced tumor burden and, in some cases, led to tumor-free survival. Administration of scFv-NKG2D in vivo also promoted survival in a murine lymphoma model. Tumor-free mice were resistant to rechallenge with cognate tumor cells, suggesting that a host-specific immunologic memory response had been generated. Host adaptive immunity including gd T cells was required for scFv-NKG2D-mediated therapeutic efficacy. ScFv-NKG2D also inhibited the growth of NKG2D ligand-negative B16F10 tumors, reduced the percentage of myeloidderived suppressor cells and regulatory T cells, and increased the infiltration of T cells, suggesting that scFv-NKG2D may target these immune suppressive cells. Together, these results establish scFv-NKG2D as a promising biological fusion protein to induce effective antitumor immunity. Cancer Res; 71(6); 2066-76. Ó2011 AACR.
Introduction
T cells can play an important role in controlling tumor growth and prolonging survival in cancer patients (1) . However, it is difficult to mount and sustain effective tumorspecific T-cell responses due to weak immunogenicity of tumor antigens, clonal deletion of high-affinity T cells, low frequency of antigen-specific T cells, downregulation of MHC molecules, and existence of immune suppressor cells and tumor-derived immunosuppressive molecules (2) (3) (4) . Although adoptive transfer of T cells can partially restore antitumor immunity, in vitro generation of large numbers of tumorspecific T cells for treatment still remains a difficult task.
Alternatively, T-cell-mediated antitumor immunity can be achieved using bispecific T-cell engagers, which bind to a surface target antigen on cancer cells and to CD3 on T cells (5) . This strategy allows T cells to recognize tumor cells and become activated irrespective of their T-cell receptor specificity and their activation by antigen-presenting cells. Recent results from a clinical trial with a CD19/CD3 bispecific antibody showed promise in cancer treatment (5, 6) .
Natural killer (NK) cells attack tumor and virally infected cells in the absence of MHC restriction, utilizing a combination of multiple activating receptors. One of these activating receptors is NKG2D. The ligands for NKG2D receptor include Rae1, Mult1, and H60 in mouse, and MICA/B and RAET1, also called ULBPs (UL-16 binding proteins), in human, which are preferentially expressed on tumor cells but not on most normal tissues (7) (8) (9) . NKG2D ligands represent ideal targets for immunotherapeutic approaches because they are selectively overexpressed on many types of tumor cells and tumorassociated suppressor cells (10, 11) . Therefore, the NKG2D receptor-NKG2D ligand system provides a relatively specific system for immune cells to recognize tumor cells and the tumor microenvironment. In this study, we describe a novel antitumor strategy based on a bispecific T-cell engager (scFv-NKG2D), in which a single-chain variable fragment (scFv) of anti-CD3e was fused to the extracellular domain of NKG2D receptor. Our hypothesis was that scFv-NKG2D would bind NKG2D ligand-positive tumor cells via NKG2D and activate T cells via anti-CD3e scFv portion, leading to elimination of the tumor and induction of host antitumor immunity. Because many types of tumor cells (leukemia, lymphoma, colon, breast, prostate, and ovarian cancers, among others) and immune suppressor cells [myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg)] express NKG2D ligands (9) (10) (11) , scFv-NKG2D targeting provides a means to engage T cells against multiple types of tumor cells and local tumor immune suppressor cells.
Materials and Methods
Mice and cell lines C57BL/6 [B6; wild type (WT)] mice were purchased from National Cancer Institute (NCI) (13) (14) (15) . Mastocytoma cell line P815/Rae1 was generated by retroviral transduction of P815 cells (H-2 d ) with a mouse NKG2D ligand, Rae1. RMA and B16F10 cells are NKG2D ligand-negative cells, whereas RMA/RG, P815/Rae1, ID8, and B3Z cells are NKG2D ligand-positive cells. Packaging cells PT67 (ATCC) and ovarian cancer ID8 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with a high glucose concentration (4.5 g/L) supplemented with 10% heatinactivated FBS (Atlanta Biologicals), 100 U/mL penicillin, 100 mg/mL streptomycin, 1 mmol/L pyruvate, 10 mmol/L HEPES, 0.1 mmol/L nonessential amino acids, and 50 mmol/L 2-mercaptoethanol. All other cell lines were cultured in RPMI plus the same supplements as in DMEM.
Construction of scFv-NKG2D
Variable regions of both heavy [V H , amino acids (aa) 1-136] and light chains (V L , without signal peptide, aa 21-128) were PCR amplified using cDNA derived from 145.2C11 hybridoma. Extracellular domain of murine NKG2D was amplified using the full-length NKG2D cDNA as a template (16) . To make antiCD3e scFv, V H and V L were joined with a 15-amino acid glycine (G)-serine (S) linker (G4S) 3 (3 repeats of GGGGS). All PCR reactions were conducted using a high-fidelity DNA polymerase Phusion (New England Biolabs). All oligos were synthesized by either Integrated DNA Technologies or SigmaGenosys. ScFv-NKG2D was created by joining anti-CD3e scFv to the extracellular domain of mouse NKG2D (aa 90-232) with a second (G4S) 3 linker. A histidine tag (6xHis) was added at the C-terminus to facilitate protein purification. The fusion gene was then cloned into a retroviral vector pFB-neo (Stratagene). A negative control fusion gene scFv-HuNKG2D was constructed by joining the scFv with the extracellular domain of human NKG2D gene.
Production of scFv-NKG2D protein
ScFv-NKG2D proteins were expressed in retroviral vector stably transduced B16F10 cells according to our previous protocols (16, 17) . Briefly, B16F10 cells were retrovirally transduced with vectors that were generated from scFv-NKG2D stably transfected packaging cell PT67 for 5 rounds. Stable B16F10 cell lines with amplified expression of scFv-NKG2D (either human or mouse version) were selected with G418 (1.5 mg/mL) for 14 days. The resulting stable B16F10 lines (B16F10/scFv-mNKG2D and B16F10/scFv-HuNKG2D) were then cultured in serum-free media (293 SFM II; Invitrogen). Supernatants were collected every 48 hours and were subjected to affinity chromatography using HisTrap columns (GE Healthcare Bio-Sciences) according to the manufacturer's instructions. Eluted fractions were then concentrated and desalted using Amicon Ultra columns (30K MWCO; Millipore). Purified scFv-NKG2D proteins were resuspended in PBS, filtered (pore size: 0.22 mm), and stored in À20
C. The integrity of scFv-NKG2D protein was determined by SDS-PAGE, followed by staining with SYPRO orange (Invitrogen), and visualized using a Typhoon 9400 imager (GE Healthcare). Concentration of scFV-NKG2D was quantitated with ImageJ software (NIH; http://rsb.info.nih.gov/nih-image/Default. html).
Flow cytometry
To determine whether scFv-NKG2D binds to CD3e, RMA cells were stained with scFv-NKG2D (0.01-1 mg/mL), followed by staining with phycoerythrin (PE)-labeled anti-mouse NKG2D monoclonal antibody (mAb) (CX5; eBioscience) or isotype control mAb. In a blocking experiment, RMA cells were preincubated with anti-CD3e (0.01-1 mg/mL; 145.2C11, eBioscience) at room temperature for 15 minutes before staining with scFv-NKG2D. Rae1 expression was determined by flow cytometry by using APC labeled pan-anti-Rae1 mAb (clone 186107; R&D Systems). Infiltration of CD4 þ and CD8 þ T cells, T-cell activation (CD69 expression), MDSCs (CD11b
, and Tregs (CD4 þ Foxp3 þ ) in tumors were determined by flow cytometry after digestion of excised, established tumors by using cocktails of DNAse and collagenase according to our previous protocol (18) . All samples were preincubated with FcR block antibody (anti-mouse CD16/CD32) to reduce nonspecific staining. Cell fluorescence was monitored using an Accuri C6 flow cytometer. Flow cytometric analysis was carried out using either Accuri or FlowJo software.
Cytokine production by T cells
To determine whether scFv-NKG2D can engage both T cells and tumor cells and lead to T-cell activation, spleen cells were stimulated with ConA and IL-2 for 4 days before coculture with tumor cells with or without scFv-NKG2D (50 ng/mL) for 24 hours. Amounts of IFN-g in supernatants were analyzed with ELISA. For tumor cells grown in suspension, coculture with preactivated murine primary T cells (10 5 ) was done in round-bottom 96-well plates at a ratio of 1:1, whereas adherent tumor cells (2.5 Â 10 4 ) were cocultured with T cells in flatbottom plates. Tumor cells were irradiated (120 Gy) before use. Cell-free supernatants were collected after 24 hours.
Twenty-four hour supernatants were assayed for IFN-g by ELISA, using DuoSet ELISA kits (R&D Systems).
Cytotoxicity assay
Lysis of target cells was determined by a 5-hour 51 Cr release assay as previously described (16, 17) .
BetaRed staining
The LacZ activity in B3Z cells was determined by using a BetaRed b-galactosidase assay kit (EMD Bioscience) according to the manufacturer's instruction.
Tumor inoculation
For the determination of effects of local expression of scFv-NKG2D on MC-38 or B16F10 tumor growth, either WT or scFv-NKG2D-transduced tumor cells (5 Â 10 5 ) were injected subcutaneously into the shaved right flank of recipient mice. Tumors were then measured every 2 days with a caliper and tumor areas were calculated. Mice were sacrificed when tumor burden became excessive. Animals were regarded as tumor free when no tumor was found 4 weeks after inoculation. For the rechallenge experiments, mice were inoculated with 10 5 WT MC-38 cells on the shaved left flank. In the systemic lymphoma model, B6 mice were injected with 10 5 RMA/RG cells via tail veins in 400 mL of HBSS. For treatment with recombinant scFv-NKG2D proteins (either mouse or human NKG2D fusion protein), mice were administered intravenously with 5 mg scFv-NKG2D on days 5, 7, and 9 post-tumor inoculations. Mice were monitored closely and sacrificed when moribund signs were observed.
Statistical analysis
Differences between groups were analyzed using Student's t test. Values of P < 0.05 were considered significant. KaplanMeier survival curves were plotted and analyzed using the GraphPad Prism software (GraphPad Software).
Results

Construction and expression of scFv-NKG2D
ScFv-NKG2D was constructed by joining anti-CD3e scFv to the extracellular domain of NKG2D receptor. The structure of scFv-NKG2D is shown in Figure 1 . Two 15-aa (G4S) 3 linkers were inserted between V H and V L and between scFv and NKG2D to allow flexible interactions among scFv-NKG2D, CD3e, and NKG2D ligands. Human NKG2D was also used to make a control fusion protein scFv-HuNKG2D because human NKG2D receptor has minimal cross-reactivity with mouse NKG2D ligands. In scFv, the antibody Fc fragment is removed. Therefore, binding of these fusion proteins to FcRpositive cells [such as macrophages, B cells, neutrophils, dendritic cells (DC), and endothelial cells via the Fc region] is eliminated, resulting in less nontumor associated T-cell activation. As shown in Figure 1B , purified scFv-NKG2D proteins are monomers at sizes around 50 kD under both native and reducing conditions, which were in line with the expected sizes of 44 kD.
ScFv-NKG2D fusion protein binds to both CD3« and NKG2D ligands
To determine whether scFv-NKG2D fusion protein preserves the binding affinity and specificity of the parental anti-CD3e 145-2C11 antibody, CD3 þ
NKG2D
À T-cell lymphoma RMA cells were stained with scFv-NKG2D (0.01-1 mg/mL), followed by staining with anti-NKG2D-PE ( Fig. 2A ). As shown in Figure 2B , scFv-NKG2D binds to CD3e in a dose-dependent manner. In addition, preincubation of RMA cells with 145-2C11 mAb (0.1-10 mg/mL) could block the binding of the scFv-NKG2D fusion protein to RMA cells in a dose-dependent manner, indicating the specific recognition of CD3e molecule by scFv-NKG2D (Fig. 2C ).
To examine whether scFv-NKG2D was capable of binding simultaneously to both T cells via scFv and tumor cells via NKG2D (Fig. 2D ), a mouse T hybridoma B3Z was used. B3Z T cells express both CD3e and an NKG2D ligand Mult1 (data not shown). We hypothesized that if scFv-NKG2D binds to CD3e and Mult1 on B3Z cells simultaneously, cross-linking of CD3e molecule will lead to activation of T cells. Because B3Z cells contain the IL-2 promoter-controlled LacZ gene as a reporter, after activation, B3Z cells will express LacZ (b-galactosidase). The ability of scFv-NKG2D to stimulate Mult1 þ B3Z cells was evaluated by measurement of the OD 570 nm or OD 550 nm values after addition of a BetaRed substrate. As expected, incubation For the convenience of protein purification, a histidine tag (6 repeats of histidine, 6xHis) was added at the C-termini. B, scFv-NKG2D proteins express as monomers.
Transiently transfected 293T cells that were cultured in serum-free media (Invitrogen) were used to express scFv-NKG2D fusion proteins. Both human (Hu, Àve control) and mouse extracellular NKG2D (Ms) portions were fused to anti-mouse CD3e scFv. Recombinant proteins were purified through nickel columns. The sizes and purity of protein samples were checked by SDS-PAGE either in native (without b-ME) or reducing conditions (with b-ME). The expressed scFv-NKG2Ds showed sizes around 50 kD, which are similar to expected 44 kD.
of B3Z cells with scFv-NKG2D, but not with control molecule scFv-HuNKG2D (human), led to cell activation in a dosedependent manner, indicating that the scFv-NKG2D can engage both T and tumor cells via NKG2D ligands. On the basis of data (Fig. 2D) , we estimate the ED 50 value of scFv-NKG2D for activating T cells was about 10 ng/mL.
ScFv-NKG2D activates primary T cells by producing IFN-g and exerting cytotoxicity
To investigate whether scFv-NKG2D stimulates primary T cells, we examined IFN-g production and cytotoxicity of T cells against tumor cells in the presence of scFv-NKG2D. ConA and IL-2 (25 U/mL) preactivated T cells were used as effector cells. As shown in Figure 3A and B, in the presence of scFv-NKG2D (50 ng/mL), T cells produced significant amounts of IFN-g after coculture with NKG2D ligand-positive cells (RMA/Rae1, P815/Rae1, and ID8) but not with ligand-negative RMA and B16F10 cells, indicating that scFv-NKG2D allows T cells to functionally recognize NKG2D ligand-bearing tumor cells. In contrast, control protein scFv-HuNKG2D does not significantly stimulate T cells to produce IFN-g in the presence of NKG2D ligand-positive tumor cells. These data indicate that anti-CD3e scFv itself has minimal ability to activate T cells under these conditions. T-cell cytotoxicity in the presence of scFv-NKG2D against various tumor cells was also determined. As shown in Figure 3C , T cells could lyse NKG2D ligandpositive target cells (P815/Rae1, ID8, and MC-38) but not the ligand-negative cell line B16F10 in vitro in the presence of scFv-NKG2D. Similar to IFN-g production, no significant killing was observed when control protein scFv-HuNKG2D was used. In addition, we also showed that scFv-NKG2D did not affect NK cell-mediated cytotoxicity against tumor cells despite the fact that incubation of high concentration (1 mg/mL) of scFv-NKG2D with tumor cells reduced surface NKG2D ligand expression ( Supplementary Fig. S1 ). , which does not express ligands for NKG2D, was stained with scFV-NKG2D (0.01-1 mg/mL), followed by staining with anti-NKG2D-PE. Samples were analyzed with an Accuri C6 flow cytometer. B, surface levels of NKG2D on RMA cells after staining with scFv-NKG2D are shown. C, anti-CD3 mAb can competitively block the binding of scFv-NKG2D to CD3 molecule in a dose-dependent manner. To confirm that scFv-NKG2D binds to CD3 molecule, RMA cells were preincubated with anti-CD3 mAb (0.1-10 mg/mL) before staining with scFv-NKG2D. D, scFv-NKG2D can activate T cells after cross-linking both CD3 and NKG2D ligands. CD3 þ and NKG2D ligand Mult1 þ T-cell hybridoma B3Z cells (10 6 /mL) were cultured in the presence of scFV-NKG2D (0.01-1 mg/mL) for 24 hours. T-cell activation (b-galactosidase activity) was analyzed using a BetaRed analysis as described in Materials and Methods. scFv-HuNKG2D fusion protein was used as a negative control because human NKG2D receptor does not cross-react with mouse NKG2D ligands.
tested for growth in vivo after subcutaneous injection. This design represents a localized scenario for scFv-NKG2D treatment that could be produced by exogenous gene transfer. MC-38 cells expressing scFv-HuNKG2D fusion protein were used as the negative control. There was no significant difference between WT and scFv-NKG2D-expressing MC-38 cells to grow in vitro (data not shown). As shown in Figure 4A , scFv-mNKG2D expression by MC-38 tumor cells significantly reduced or prevented tumor growth compared with WT and scFv-HuNKG2D-expressing MC-38 tumor cells. Fifty-nine percent of B6 mice (13/22) receiving MC-38/scFv-mNKG2D tumor cells were tumor-free after 30 days. In a second and more stringent model, lymphoma-bearing mice that had been given NKG2D ligand-positive T-cell lymphoma RMA/RG cells intravenously were treated with 3 doses of either recombinant scFv-mNKG2D (5 mg per dose i.v.) or scFv-HuNKG2D (specificity control). As shown in Figure 4B , systemic administration of scFv-mNKG2D significantly improved survival of tumorbearing mice. The median survival increased from 18 days (HBSS) to 31 days (P < 0.01), whereas treatment with control molecule scFv-HuNKG2D lead only to median survival of 23 days. In addition, 39% (7/18) of the scFv-mNKG2D-treated lymphoma-bearing mice were tumor free after 45 days. As for toxicity, the animals treated with scFv-mNKG2D proteins did not show any overt evidence of inflammatory damage (e.g., ruffled hair, hunchback, or diarrhea), suggesting there was no overt toxicity (data not shown).
To determine whether treatment with scFv-NKG2D induced a host memory response against WT tumor cells, scFv-NKG2D-treated mice that had remained tumor free after 45 days were challenged with either WT MC-38 (10 5 ) or RMA (NKG2D ligand-negative, 10 4 ) cells on their left flank. These tumor-free mice were resistant to a subsequent challenge of the same type of tumor cells, whereas all control naive mice had large tumors after 3 weeks (Fig. 4C and D) . This observation indicated that scFv-NKG2D treatment induced hosts to generate specific immunologic memory against tumor antigens. 
Host adaptive immunity is involved in scFv-NKG2D-mediated antitumor efficacy
Because scFv-NKG2D protein uses T cells to target tumor cells, it is expected that the absence of T cells would render scFv-NKG2D treatment ineffective in reducing tumor growth. To test this hypothesis, either WT MC-38 or scFv-NKG2D-expressing MC-38 cells (MC-38/scFv-NKG2D) were inoculated (at a dose of 5 Â 10 5 cells) subcutaneously into B6.RAG1 À/À mice, which lack T and B lymphocytes. As expected, both WT and MC-38/scFv-NKG2D cells grew progressively in B6. RAG1 À/À mice (Fig. 5A) . Thus, lymphocytes play an obligate role in scFv-NKG2D-mediated antitumor growth in vivo. gd T cells constitute a major T-cell subset in skin and intestine and can be harnessed for cancer immunotherapy (19) . Therefore, scFv-NKG2D may mobilize and activate gd T cells against subcutaneous tumors, resulting in tumor reduction. The role of gd T cells was investigated by inoculating either WT MC-38 or scFv-mNKG2D-expressing MC-38/scFv-NKG2D cells into TCRa-deficient mice, in which ab T cells are deficient and gd T cells remain intact (20) . MC-38 cells that express scFv-NKG2D show markedly slower growth than those that express WT tumors (Fig. 5A) . However, no tumor-free mice were obtained. This result suggests that gd T cells play a role in scFv-NKG2D-mediated therapeutic efficacy against subcutaneous tumors but ab T cells are also required for efficient antitumor effects.
Tumor-associated host cells play roles in scFv-NKG2D-mediated antitumor efficacy
Several studies have shown that some immune cells, such as Tregs and MDSCs express NKG2D ligands (10). Nausch and colleagues showed that CD11b
from tumor-bearing mice but not myeloid cells from naive mice expressed an NKG2D ligand, Rae1. Interestingly, these tumor-associated MDSCs can stimulate NK cells to produce IFN-g in a manner that is partially dependent on the interaction between NKG2D and its ligands (10) . In fact, NKG2D can be used to target Tregs at the tumor site in ovarian cancer (11) . To determine whether tumor-associated host cells are involved in scFv-NKG2D-mediated therapeutic efficacy, we tested the effects of local expression of scFv-NKG2D on the growth of B16F10 tumors, which do not express NKG2D ligands in vitro or in vivo (Supplementary Fig. S3 ). If B16F10 tumor-associated host cells (such as MDSCs and Tregs) are targeted by scFv-NKG2D, it would be expected that B16F10 tumor growth may be reduced by the local expression of scFv-NKG2D. As shown in Figure 5B , local expression of scFv-NKG2D significantly reduced B16F10 tumor growth, suggesting that scFv-NKG2D may target ligand-positive, tumor-associated host cells. There was no difference between B16F10 and B16F10/scFv-NKG2D in terms of in vitro growth (Supplementary Fig. S4 ).
To further understand whether Tregs and MDSCs can be targeted, we first checked the NKG2D ligand Rae1 expression on those cells in both MC-38 and B16F10 models. As shown in Supplementary Figure S5C , Rae1 was expressed on tumor (both MC-38 and B16F10)-derived Tregs (CD4 þ Foxp3 þ ) and
þ cells from naive B6 spleens did not express Rae1, suggesting that tumor microenvironment plays a role in NKG2D ligand expression. Next, it was tested whether local expression of scFv-NKG2D could alter the ratios of effector CD4 þ /Treg and Gr1
the B16F10 melanoma model. If tumor-derived Tregs and MDSCs were targeted, one would expect lower percentages of these cells in tumors. As shown in Figure 6 , local expression of scFv-NKG2D by B16F10 cells significantly (P < 0.01) reduced the percentage of both Tregs (Fig. 6A) and MDSCs (Fig. 6B) at the tumor site. In addition, Rae1 expression by those cells was lower in the presence of scFv-NKG2D (Fig. 6C) , consistent with the targeting of tumor-derived Tregs and MDSCs by scFV-NKG2D. Overall, these data support the idea that NKG2D can be used to target both tumor cells and their supportive immunosuppressive cells.
Local expression of scFv-NKG2D leads to increased recruitment of T cells Because local expression of scFv-NKG2D resulted in reduced tumor growth, we hypothesized that more T cells may be recruited to tumor sites and become more activated. Figure 7A and C, the percentage of both CD4 þ and CD8 þ T cells was significantly increased in the presence of scFv-NKG2D. In addition, T cells (especially CD8 þ T cells) had a significantly increased expression of CD69, which was consistent with an activated status ( Fig. 7B and D) .
Discussion
Immunotherapy has emerged as a promising method to treat cancers due to the ability to selectively eliminate tumors. Both vaccination and adoptive immune cell transfer have been utilized against cancers (3). DC-based vaccines have been tested in both animal models and clinical trials. However, DCs need to be delicately conditioned with toll-like receptor agonists and cytokines to ensure delivery of both primary and costimulatory signals for T-cell stimulation (21) . Otherwise, T cells may be induced into a tolerant state. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients (22) . In the second strategy, adoptive transfer of T cells or allogeneic bone marrow cells can be carried out (23) . However, the traditional approaches for obtaining large numbers of tumor-specific T cells are difficult. Allogeneic bone marrow transplantation can cause severe acute graft-versus-host disease, and response rate is less than 15% (23) . Compared with these 2 strategies, scFV-NKG2D no longer relies on generation of specific T cells or a regular antigen presentation by DCs. scFv-NKG2D stimulates host T cells in an MHC-independent manner. Therefore scFv-NKG2D is unlikely to be affected by well-documented tumor-escape strategies, such as "downregulation" of MHC expression. Unlike most of other bispecific molecules in which a specific tumor-targeting scFv has to be made for targeting certain types of tumors, scFv-NKG2D is a pan-tumor-targeting reagent because NKG2D ligands are expressed on many types of tumor cells (colon, ovarian, breast, prostate, melanoma, leukemia, and lymphoma, among others). In addition, NKG2D ligands have restricted expression in normal tissues (9), but they are also expressed on immunosuppressive cells within the tumor microenvironment.
In this study, scFv-NKG2D treatment reduced or abrogated the growth of NKG2D ligand-positive tumors, suggesting that scFv-NKG2D in vivo can lead to effective T-cell activation and elicit host T-cell responses to tumor cells. Possible mechanisms for this may be the small size of scFv-NKG2D ($50 kD) and existence of flexible linkers which allow efficient formation of immunologic synapses and reduce a steric barrier imposed by large, abundant glycoproteins such as CD43 and CD45 (24) . In adult humans, about one half of the T cells are memory cells based on the expression of a memory marker CD45RO and their ability to respond to allogeneic cells (25) . Therefore, these memory T cells may be primed by NKG2D ligand-positive tumor cells in the presence of scFv-NKG2D even without the help of costimulatory molecules. Full-length anti-CD3 mAb, even in very small quantities, can induce T-cell activation and its associated toxicity in vivo (26) . Nonspecific T-cell activation is primarily due to antibody Fc fragment binding to FcR, which leads to CD3 cross-linking, because anti-CD3-induced nonspecific T-cell activation was significantly reduced using enzymatically produced F(ab 0 ) (26, 27) . In scFv-NKG2D, the Fc fragment was removed. Therefore, nonspecific T-cell activation due to Fc-mediated events and related toxicities are expected to be low.
Immunosuppressive cells within the tumor microenvironment have been shown to prevent antitumor immunity (28, 29) . Effective therapies must not only attack the tumor but must also change the local microenvironment leading to In TCRa À/À mice, ab T cells are lacking whereas gd T cells remain normal (20) . As shown in Figure 7 , scFv-NKG2D expression by MC-38 cells also reduced tumor growth in TCRa À/À mice, suggesting that host gd T cells can be redirected against NKG2D ligand-positive tumors by scFv-NKG2D. gd T cells are abundant in skin and mucosa tissues (31) . Many studies have suggested that gd T cells are important components in antitumor immunity (32, 33) . Therefore, in this model, gd T cells may play a significant role in scFv-NKG2D-mediated early antitumor responses.
Because NKT cells also express CD3, it is possible that scFv-NKG2D may engage NKT cells to tumor cells, leading to antitumor responses. It has been shown that administration of a-galactosylceramide (aGalCer, an agonist of NKT cells), aGalCer-loaded DCs, or aGalCer-loaded soluble CD1d molecule (aGalCer/sCD1d) could induce significant IFNg-producing NKT responses and protect against the development of metastases with B16 melanoma after (34, 35) . However, success of aGalCer treatment in humans has been limited. The partial reason may be that in humans, there exist anti-a-linked sugar natural antibodies that do not exist in the mouse (36, 37) . Lung and liver contain abundant NKT cells, which may play an important role in keeping tumor metastasis in check (34, 35, 38) . Expression of membrane-bound anti-CD3 scFv and CD86 on B16 melanoma cells has been shown to suppress tumor growth in vivo and protect mice from B16 rechallenge. In the subcutaneous B16 model, NKT cells have been shown to play a critical role in in vivo antitumor activity (39) . Therefore, it is possible that scFv-NKG2D may also engage both NKT and tumor cells, resulting in vivo antitumor activity.
T-cell infiltration into tumors (especially CD8 þ T cells) is often correlated with improved survival (40) (41) (42) . Recent studies have shown that tumor-specific CD4 þ T cells could also differentiate in vivo into cytotoxic T cells and induce regression of established melanoma (43, 44) . The results that local expression of scFv-NKG2D increased recruitment of T cells and reduced tumor growth are consistent with these findings. The possible mechanisms for enhanced T-cell infiltration after scFv-NKG2D treatment may be that scFv-NKG2D engages NKG2D ligand-positive cells in Regulation of NKG2D ligand expression can occur on multiple levels (transcriptional, posttranscriptional, and posttranslational levels; ref. 9). DNA pathways initiated by ATM (ataxia telangiectasia, mutated) or ATR (ATM-and Rad3-related) protein kinases have been shown to play important roles in upregulation of NKG2D ligands (45) . Many anticancer drugs can also upregulate NKG2D ligands (46) , which not only potentially enhances the host NK cell antitumor activity but also suggests possible synergistic effects of these drugs with scFv-NKG2D treatment.
In view of the wide expression of NKG2D ligands on many human cancers and Tregs and MDSCs, the strategy described here has a promising potential to treat many human cancers by direct and indirect mechanisms. The ability of scFv-NKG2D to induce long-term immunologic memory may be beneficial to cancer patients with minimal residual disease. Collectively, our findings suggest that scFv-NKG2D represents a promising alternative to elicit host immunity for effective immunotherapy against cancer.
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